Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28524227 | 0.84 | RAB9A (0.64) | ALDH1A1RAB9ANPC1MAPTPDE4D | |
| SCHEMBL6070622 | 0.81 | PDE4D (0.76) | ALDH1A1RAB9ANPC1MAPTPDE4D | |
| SCHEMBL13982922 | 0.78 | RIPK2 (0.61) | RIPK2ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL11654025 | 0.77 | ALDH1A1 (0.46) | RIPK2ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL23402128 | 0.76 | ALDH1A1 (0.54) | RIPK2ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL11653918 | 0.76 | SMN1; SMN2 (0.69) | RIPK2ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL15428639 | 0.75 | ALDH1A1 (0.60) | RIPK2ALDH1A1SCN9ARPA1 | |
| SCHEMBL11654019 | 0.74 | ALDH1A1 (0.49) | RIPK2ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL3828501 | 0.74 | NPC1 (0.57) | RAB9ANPC1 | |
| SCHEMBL2201890 | 0.73 | LMNA (0.64) | ALDH1A1RAB9ANPC1MAPTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | claimed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | claimed |
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | RIPK2 2526/4885ALDH1A1 775/4885RAB9A 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.